Palvella Therapeutics (PVLA) vs. Its Competitors Financial Comparison

Palvella Therapeutics (NASDAQ:PVLA) is one of 1,068 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare Palvella Therapeutics to related companies based on the strength of its institutional ownership, valuation, analyst recommendations, earnings, profitability, dividends and risk.

Institutional & Insider Ownership

40.1% of Palvella Therapeutics shares are held by institutional investors. Comparatively, 44.1% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 6.4% of Palvella Therapeutics shares are held by insiders. Comparatively, 13.6% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Palvella Therapeutics and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Palvella Therapeutics	$42.81 million	-$24.54 million	-1.59
Palvella Therapeutics Competitors	$1.84 billion	$140.61 million	-7.56

Palvella Therapeutics’ peers have higher revenue and earnings than Palvella Therapeutics. Palvella Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

Palvella Therapeutics has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, Palvella Therapeutics’ peers have a beta of 3.66, meaning that their average stock price is 266% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Palvella Therapeutics and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	0	0	4	0	3.00
Palvella Therapeutics Competitors	8137	21793	49588	1308	2.55

Palvella Therapeutics presently has a consensus price target of $40.33, indicating a potential upside of 109.85%. As a group, “Pharmaceutical preparations” companies have a potential upside of 239.80%. Given Palvella Therapeutics’ peers higher probable upside, analysts plainly believe Palvella Therapeutics has less favorable growth aspects than its peers.

Profitability

This table compares Palvella Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-80.93%	-59.55%
Palvella Therapeutics Competitors	-3,409.82%	-236.05%	-32.89%

Summary

Palvella Therapeutics peers beat Palvella Therapeutics on 8 of the 13 factors compared.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.